Khurana Daksh, Kumar Binesh, Devi Jai, Antil Nidhi, Patil Rajesh B, Singh Khushwant, Singh Yudhvir
Department of Computer Science & Engineering, Symbiosis Institute of Technology, Pune, 412115, Maharashtra, India.
Department of Chemistry, Guru Jambheshwar University of Science and Technology, Hisar, 125001, Haryana, India.
Heliyon. 2024 Jun 15;10(12):e33150. doi: 10.1016/j.heliyon.2024.e33150. eCollection 2024 Jun 30.
In the previous study, the synthesis and characterization of 4-(3-fluorophenyl)-3-thiosemicarbazide and benzaldehyde derivatives based thiosemicarbazone ligands and their Co(II), Ni(II), Cu(II), Zn(II) complexes were carried out to evaluate their malarial and oxidant and inflammatory inhibition abilities, demonstrating that these compounds have robust efficacy for these ailments. In the present research, to find out a combating agent against breast cancer, tuberculosis, bacterial and fungal ailments, the compounds were tested through MTT, microplate alamar blue and serial dilution protocols. ADMET and DFT investigation were analyzed against highly bioactive compounds (2, 7-10) to give a new insight about compound's reactivity, stability and drug likeness properties. Furthermore, activity results shows that the ligand (2) and its complexes demonstrate greater efficacy compared to ligand (1) and its complexes. The Cu(II) and Zn(II) complexes were observed as highly efficient for breast cancer (MCF-7 cell line), TB (HR strain), bacterial and fungal ailments in comparison of standard drugs with 0.029 ± 0.001 μM IC value for in anticancer activity and 0.0034 ± 0.0017 μmol/mL MIC value for in anti-tuberculosis activity. In the molecular docking investigation, the various kind of binding interactions and lowest binding affinity of (against 4RJ3 (-10.0 kcal/mol), 2VCJ (-7.9 kcal/mol)) and (-7.8 and -8.3 kcal/mol for 5V3Y and 3PTY protein) support their bioactivity. This research highlights the pharmaceutical importance of transition metal complexes having thiosemicarbazones, presenting a significant approach for the discovery of potent anti-infectious agent.
在先前的研究中,开展了基于4-(3-氟苯基)-3-硫代氨基脲和苯甲醛衍生物的硫代氨基脲配体及其钴(II)、镍(II)、铜(II)、锌(II)配合物的合成与表征,以评估它们对疟疾、氧化和炎症的抑制能力,结果表明这些化合物对这些疾病具有强大的疗效。在本研究中,为了找出一种对抗乳腺癌、结核病、细菌和真菌疾病的药物,通过MTT、微孔板alamar蓝和系列稀释方案对这些化合物进行了测试。针对高生物活性化合物(2, 7 - 10)进行了ADMET和DFT研究,以深入了解化合物的反应性、稳定性和药物相似性。此外,活性结果表明,配体(2)及其配合物比配体(1)及其配合物表现出更高的疗效。与标准药物相比,观察到铜(II)和锌(II)配合物对乳腺癌(MCF - 7细胞系)、结核病(HR菌株)、细菌和真菌疾病具有高效性,抗癌活性的IC值为0.029±0.001 μM,抗结核活性的MIC值为0.0034±0.0017 μmol/mL。在分子对接研究中,各种结合相互作用以及(针对4RJ3 (-10.0 kcal/mol)、2VCJ (-7.9 kcal/mol))和(针对5V3Y和3PTY蛋白分别为-7.8和-8.3 kcal/mol)的最低结合亲和力支持了它们的生物活性。本研究突出了具有硫代氨基脲的过渡金属配合物的药学重要性,为发现有效的抗感染药物提供了一种重要方法。